Zynerba Pharmaceuticals — Investor Presentation (September 2022)
40 slides from Zynerba Pharmaceuticals's investor presentation, Sep 13, 2022
Slide 1: Next-Generation Transdermal Cannabinoid Therapeutics
© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. Next - Generation Transdermal Cannabinoid Therapeutics September 2022
Slide 2: Forward-Looking Statements
Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among other things relate to the future operations, opportunities or financial performance of Zyn e
Slide 3: A different and exciting approach to Cannabidiol
A different and exciting approach to Cannabidiol
Slide 4: An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company
An Orphan - Focused Neuropsychiatric, Biopharmaceutical Company June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 4 Permeation - enhanced Patent - protected through 2038 Pharmaceutically manufactured; THC free FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL One Phase 3 clinica
Slide 5: Benefits of Our Approach to Cannabidiol
Benefits of Our Approach to Cannabidiol June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 5 FDA regulated Consistency of production Purity of ingredients No THC – not a scheduled drug by U.S. DEA Scalable production process PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL DISP
Slide 6: Clinical Development Programs
Clinical Development Programs Fragile X Syndrome FXS 22q Deletion Syndrome 22q Autism Spectrum Disorder ASD
Slide 7: Overlap of Symptoms Across Conditions
Overlap of Symptoms Across Conditions June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 7 Anxiety Seeks Isolation Social Avoidance Lack of Interaction Attention Deficits Irritability FXS 22q ASD
Slide 8: Focused Clinical Pipeline
Fragile X Syndrome (FXS) Focused Clinical Pipeline June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 8 Preclinical Phase 1 Phase 2 Pivotal Market 22q Deletion Syndrome (22q) Autism Spectrum Disorder (ASD) Regulatory Filing U.S. Orphan Drug and Fast Track designations; EU
Slide 9: Well-Tolerated Safety Profile
• Zygel safety database across all clinical studies includes data from over 900 volunteers and patients • Majority of treatment - emergent AEs (TEAE) were mild or moderate • Most common Zygel - related TEAE are application site events, the majority of which were mild and transient • No clinically si
Slide 10: Fragile X Syndrome
[ Fragile X Syndrome ane a
Slide 11: What is Fragile X Syndrome (FXS)
~78K U.S. PATIENTS What is Fragile X Syndrome (FXS) June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 11 • Leading known cause of inherited intellectual disability and autism spectrum disorder • Mutation of the FMR1 gene causes endocannabinoid system (ECS) dysregulation •
Slide 12: Poised for Success in FXS
Poised for Success in FXS June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 12 Largest clinical trial ever conducted in children with FXS Extensive safety database Patients on drug for up to five years Statistically significant outcomes in children with complete methylati
Slide 13: Role of FMR1 Methylation in FXS
Role of FMR1 Methylation in FXS June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 13 • FMR1 gene codes for production of FMRP* which is vital to synapse development • Methylation of the FMR1 gene plays a role in determining gene function • When methylation of the FMR1 gen
Slide 14: CONNECT-FX Trial Key Learning: Complete Methylation Results
CONNECT - FX Trial Key Learning: Results with complete methylation of FMR1 gene Consistent Improvements Observed with Zygel vs. Placebo in Patients with Complete Methylation June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 14 PRIMARY ENDPOINT CAREGIVER REPORTED BEHAVIOR
Slide 15: Change in ABC-C FXS Social Avoidance
Change in ABC - C FXS Social Avoidance June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 15 Clinically Meaningful Change a Achieved and Maintained in Patients with Complete Methylation of FMR1 Gene b 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1
Slide 16: Design Optimized from CONNECT-FX Trial
Design Optimized from CONNECT - FX Trial June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 16 More patient and family friendly Extending trial to 18 - weeks Increased dosing option for individuals >50 kg Successful completion of Phase 3 pivotal trial expected to satisfy r
Slide 17: Confirmatory Pivotal Trial Design
Confirmatory Pivotal Trial Design June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 17 Double - Blind, Placebo - Controlled Study: Initiated 18 weeks 3 to 17 years old Moderate - to - Severe FXS Zygel (n~100; 80*) 250 mg daily (≤30kg) 500 mg daily (>30kg) 750 mg daily (>5
Slide 18: Trial Objectives
Trial Objectives June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 18 Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale in patients who have complete (100%) methylation of their FMR1 gene • Change from baseline to end of treatment in: • ABC
Slide 19: Next Steps in FXS
Next Steps in FXS June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 19 Continued RECONNECT pivotal trial enrollment Topline results expected in 2H 2023
Slide 20: 22q11.2 Deletion Syndrome (22q)
22q11.2 Deletion Syndrome (22q) Image courtesy Positive Exposure © 2016 Positive Exposure. All rights reserved. www.PositiveExposure.org . Eliza, living with 22q11.2 deletion syndrome
Slide 21: What is 22q11.2 Deletion Syndrome (22q)?
What is 22q11.2 Deletion Syndrome (22q)? June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 21 • Rare disorder and second most common genetic disorder, behind Down s yndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically c
Slide 22: Rationale for Zygel in 22q
U.S. ORPHAN DRUG DESIGNATION GRANTED FOR TREATMENT OF 22q Rationale for Zygel in 22q June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 22 • Overlapping symptoms with FXS and ASD • Associated with increased anxiety, irritability, social withdrawal and social interaction pr
Slide 23: INSPIRE Phase 2 Trial Design
INSPIRE Phase 2 Trial Design June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 23 Period 1: Completed 14 weeks 4 to 15 years old With 22q11.2 Deletion Syndrome Zygel (n = 20) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight - based dose) Period 2: Ongoing 24 weeks Effica
Slide 24: INSPIRE Period 1 Results
• Statistically significant improvements at 14 weeks of treatment compared to baseline for multiple efficacy assessments: • The total score and all five subscales of the Anxiety, Depression and Mood Scale (ADAMS) • All five subscales of the Aberrant Behavior Checklist – Community (ABC - C) • Pediatr
Slide 25: Significant Improvement in Anxiety as Measured by the PARS-R
Efficacy: Significant Improvement in Anxiety as Measured by the PARS - R June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 25 Mean PARS - R Scores and Percentage Improvement PARS - R, Pediatric Anxiety Rating Scale - Revised. 14.7 8.5 0 2 4 6 8 10 12 14 16 40.6% ( P =.000
Slide 26: Significant Improvements in ADAMS and ABC-C Scores
Efficacy: Significant Improvements in ADAMS Total and Subscale Scores and All ABC - C Subscale Scores June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 26 ADAMS, Anxiety, Depression, and Mood Scale. 45.3% ( P =.0005) The efficacy analysis included 16 patients for ADAMS (1
Slide 27: Next Steps in 22q
Next Steps in 22q June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 27 Discuss regulatory pathway with FDA Initiate Phase 3 program after FDA discussions and RECONNECT topline results
Slide 28: Autism Spectrum Disorder
Autism Spectrum Disorder
Slide 29: Rationale for Zygel in Autism Spectrum Disorder (ASD)
Rationale for Zygel in Autism Spectrum Disorder (ASD) June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 29 • Results from FXS trials suggested spectrum of activity against behaviors also seen in ASD: irritability, social avoidance and anxiety • Studies suggested ASD is li
Slide 30: BRIGHT Open-label Phase 2 Trial Design
BRIGHT Open - label Phase 2 Trial Design June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 30 Period 1 14 weeks 3 to 1 6 years old Moderate - to - Severe ASD Zygel (n = 37) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight - based dose) Period 2 24 weeks 18 Patients with
Slide 31: BRIGHT Period 1 Results
BRIGHT Phase 2 Trial Results: Period 1 Statistically Significant Results at Week 14 Compared to Baseline (Completers in Efficacy Population n=28 † ) June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 31 † n=26 for ABC - C inappropriate speech; *Statistically significant; F
Slide 32: BRIGHT Period 2 Results Sustained Through Week 38
50% ( P< 0.0001 ) 61% ( P <0.0001) 60% ( P <0.0001) 53% ( P <0.0001) 56% ( P <0.0001) 0 5 10 15 20 25 30 35 40 Irritability Inappropriate Speech Stereotypy Social Withdrawal Hyperactivity ABC - C Subscale Score Mean Scores Baseline Week 14 Week 38 BRIGHT Period 2 Results: Statistically Significant I
Slide 33: Next Steps in ASD
Next Steps in ASD June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 33 Submit Investigational New Drug (IND) application specific to ASD with finalized clinical protocol ASD is now third in priority and initiation of Phase 3 program is deferred at this time
Slide 34: Positioned for Success
Positioned for Success
Slide 35: Leadership
Leadership June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 35 Armando Anido Chairman of the Board and CEO Terri B. Sebree President Jim Fickenscher CFO and VP, Corporate Development Paul Kirsch VP, Regulatory Affairs and Quality Assurance Joe Apostolico VP, Human Resour
Slide 36: Financial Strength
Financial Strength June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 36 CASH AND CASH EQUIVALENTS $62.5M as of June 30, 2022; expected to be sufficient to fund operations and capital requirements through th e end of 2023/early 2024 BALANCE SHEET CLEAN No debt, 45.8M share
Slide 37: A Year of Clinical Progress Ahead
A Year of Clinical Progress Ahead June 2022 Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 37 Fragile X Syndrome (FXS) Autism Spectrum Disorder (ASD) 22q Deletion Syndrome (22q) U.S. Orphan Drug and Fast Track designations; EU Orphan Drug designation U.S. Orphan Drug designation
Slide 38: Zynerba Vision for Future Growth
• Launch Zygel for FXS into a $1.9B+ U.S. market opportunity • Establish a fully integrated organization with U.S. commercial presence • Preparing for EU approval in FXS • Advance 22q and ASD Ph3 programs towards completion • Leaders in transdermal cannabidiol delivery • Late - stage clinical compan
Slide 39: A different and exciting approach to Cannabidiol
A different and exciting approach to Cannabidiol
Slide 40: Thank you!
© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Thank you!
Zynerba Pharmaceuticals — Investor Presentation (September 2022) on 6ix